Metro Inc
TSX:MRU
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
88.56
107.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Metro Inc
Metro Inc., a stalwart in the Canadian retail landscape, navigates the competitive corridors of the grocery and pharmaceutical sectors with precision and acumen. Founded in 1947, Metro has grown from a humble beginning in Quebec to a significant force across the provinces, marking its presence with an expansive network of supermarkets, discount stores, and pharmacy outlets. The company's operations are neatly divided into two main segments: food and pharmaceuticals. Metro's grocery segment operates under well-recognized banners such as Metro, Super C, and Food Basics, offering a diverse array of products ranging from fresh produce and meats to private-label merchandise. This segment’s success hinges on Metro’s ability to adapt to consumer tastes and utilize data-driven strategies for inventory management, thereby optimizing both the customer shopping experience and logistical efficiency.
Parallel to its grocery operations, Metro has built a robust pharmaceutical division through its affiliation with Jean Coutu and other pharmacy brands. This segment provides not only prescription medications but also a comprehensive suite of health, beauty, and wellness products. The synergy between the food and pharmaceutical divisions allows Metro to leverage cross-category shopping trends and customer loyalty programs, fostering a one-stop-shop format that resonates with its clientele. Revenue generation is anchored in the company's strategic pricing models, high-volume sales, and the continuous enhancement of private-label offerings, all orchestrated to maintain a balance between competitive pricing and profit margins. Through thoughtful expansions and acquisitions, Metro Inc. has crafted a diversified yet cohesive portfolio that drives sustainable growth and strengthens its positioning in the ever-evolving retail marketplace.
Metro Inc., a stalwart in the Canadian retail landscape, navigates the competitive corridors of the grocery and pharmaceutical sectors with precision and acumen. Founded in 1947, Metro has grown from a humble beginning in Quebec to a significant force across the provinces, marking its presence with an expansive network of supermarkets, discount stores, and pharmacy outlets. The company's operations are neatly divided into two main segments: food and pharmaceuticals. Metro's grocery segment operates under well-recognized banners such as Metro, Super C, and Food Basics, offering a diverse array of products ranging from fresh produce and meats to private-label merchandise. This segment’s success hinges on Metro’s ability to adapt to consumer tastes and utilize data-driven strategies for inventory management, thereby optimizing both the customer shopping experience and logistical efficiency.
Parallel to its grocery operations, Metro has built a robust pharmaceutical division through its affiliation with Jean Coutu and other pharmacy brands. This segment provides not only prescription medications but also a comprehensive suite of health, beauty, and wellness products. The synergy between the food and pharmaceutical divisions allows Metro to leverage cross-category shopping trends and customer loyalty programs, fostering a one-stop-shop format that resonates with its clientele. Revenue generation is anchored in the company's strategic pricing models, high-volume sales, and the continuous enhancement of private-label offerings, all orchestrated to maintain a balance between competitive pricing and profit margins. Through thoughtful expansions and acquisitions, Metro Inc. has crafted a diversified yet cohesive portfolio that drives sustainable growth and strengthens its positioning in the ever-evolving retail marketplace.
Revenue Growth: Metro reported fourth quarter sales of $5.1 billion, up 3.4% from last year, driven by gains in discount and pharmacy segments.
Gross Margin Improvement: Gross margin increased to 20% of sales, up from 19.7% last year, supported by better shrink and productivity gains.
DC Disruption Costs: The Toronto freezer shutdown cost Metro $22.5 million after tax in Q4, with another $15–20 million expected in Q1 due to contingency measures.
Pharmacy Strength: Pharmacy same-store sales rose 4.8%, with prescription sales up 5.5% and commercial sales up 2.9%.
EPS and Net Earnings: Adjusted net earnings grew 8.6% to $246 million, and adjusted EPS increased 10.8% to $1.13.
CapEx Outlook: Capital expenditures were $511 million in fiscal '25 and are expected to rise to about $550 million in fiscal '26.
Outlook Stable: Management sees Q1 trends similar to Q4, expects DC operations to normalize by year-end, and continues to focus on efficiency and discount store expansion.